Abstract 448P
Background
Chemotherapy efficacy depends on relative dose intensity (RDI) and an RDI <85% is associated with unfavourable overall survival. Clinicopathological characteristics have been observed as risk factors of reduced RDI. The pro-inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP), which also serve as biomarkers of aging, have been reported to associate with RDI. We aimed to determine whether these parameters have influence on RDI in the local breast cancer (BC) patients.
Methods
This cross-sectional study recruited 172 women with stage I-IV BC receiving first-line chemotherapy between July 2018-March 2022. Sociodemographic, clinicopathological, and treatment data and peripheral blood samples were collected prior to chemotherapy. IL-6 and CRP levels were analyzed using quantitative ELISA. Dose reductions and delays were captured and utilized to calculate the patient’s RDI. Multivariable logistic regression analysis was performed to determine the association between pre-chemotherapy parameters and RDI <85%.
Results
Mean age was 52 years (range 32-78). The average RDI for all patients was 93% and an RDI <85% occurred in 23 (13.4%) patients. Mean IL-6 level was 1.12 pg/ml (range 0.0–27.7) and mean CRP was 10.82 μg/ml (range 0.0–151.7). Factors associated with reduced RDI were diabetes mellitus comorbidity (OR 5.13, 95% CI 1.38–19.03; p =0.015), triple-negative tumours (OR 4.17, 95% CI 1.09–15.89; p =0.037), palliative treatment setting (OR 3.75, 95% CI 1.12–12.62, p =0.032), and IL-6 serum level >0.485 pg/ml (OR 3.46, 95% CI 1.05–11.37; p =0.041).
Conclusions
The presence of diabetes mellitus comorbidity, triple-negative tumours, palliative treatment intention, and IL-6 serum level >0.485 pg/ml are associated with reduced RDI. Further investigation is warranted to confirm the association between biomarker of aging and chemotherapy delivery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, The Ministry of Education, Culture, Research, and Technology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract